0.485
-0.02 (-3.00%)
| Previous Close | 0.500 |
| Open | 0.482 |
| Volume | 8,716 |
| Avg. Volume (3M) | 169,324 |
| Market Cap | 112,457,920 |
| Price / Book | 208.12 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 - 3 Mar 2025 |
| Operating Margin (TTM) | -369.31% |
| Diluted EPS (TTM) | -0.100 |
| Quarterly Revenue Growth (YOY) | -39.40% |
| Total Debt/Equity (MRQ) | 455.33% |
| Current Ratio (MRQ) | 0.340 |
| Operating Cash Flow (TTM) | -13.01 M |
| Levered Free Cash Flow (TTM) | -7.74 M |
| Return on Assets (TTM) | -238.11% |
| Return on Equity (TTM) | -1,277.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | RECCE LTD FPO [RCE] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.75 |
|
Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. The company operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat diseases caused by various bacteria namely Sepsis, Neisseria gonorrhoeaei, Escherichia coli, Mycobacterium abscessus, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 33.58% |
| % Held by Institutions | 6.53% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |